Collegium Pharmaceutical, Inc. (COLL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Collegium Pharmaceutical (NASDAQ:COLL) CEO Vikram Karnani, presenting at the Morgan Stanley Global Healthcare Conference on September 8, 2025, highlighted 2025 as a productive year for the company. A key strategic priority outlined was accelerating the growth of Jornay PM, a product acquired through the Ironshore Therapeutics acquisition approximately a year prior, which marked Collegium's entry into the ADHD market.

Analysis

In a presentation at the Morgan Stanley Global Healthcare Conference, Collegium Pharmaceutical's CEO, Vikram Karnani, characterized 2025 as a 'productive year' and reinforced the company's strategic priorities. The central focus is the acceleration of growth for Jornay PM, an ADHD treatment acquired through the purchase of Ironshore Therapeutics approximately one year ago. This acquisition represents a significant strategic pivot, marking Collegium's entry into the ADHD market, which management views as an 'exciting new space.' The commentary, which registers a strongly positive sentiment score of 0.65, positions the successful commercialization of Jornay PM as the key driver for the company's near-term performance and the primary narrative for investors. While the update is optimistic, it remains qualitative, lacking specific financial metrics on the product's performance to date.

Key Decisions for Investors

• Investors should closely monitor prescription volume and sales data for Jornay PM, as management has explicitly designated it as the primary growth driver for the company.
• The successful commercialization of Jornay PM serves as a critical test of management's post-acquisition execution capabilities, making its market penetration and revenue contribution key performance indicators to watch in upcoming quarters.
• Given the qualitative nature of the CEO's update, it is prudent to await concrete financial metrics in subsequent earnings reports to quantify the actual growth and profitability of the new ADHD franchise before adjusting valuation models.